What is the official website of Novartis Brasil ?

The official website of Novartis Brasil is https://www.novartis.com.br/.

What is Novartis Brasil's cybersecurity risk score?

Novartis Brasil has an AI-generated cybersecurity risk score of 758 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Novartis Brasil experienced?

According to Rankiteo, Novartis Brasil currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Novartis Brasil been affected by any supply chain cyber incidents ?

According to Rankiteo, Novartis Brasil has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Novartis Brasil have SOC 2 Type 1 certification ?

According to Rankiteo, Novartis Brasil is not certified under SOC 2 Type 1.

Does Novartis Brasil have SOC 2 Type 2 certification ?

According to Rankiteo, Novartis Brasil does not hold a SOC 2 Type 2 certification.

Does Novartis Brasil comply with GDPR ?

According to Rankiteo, Novartis Brasil is not listed as GDPR compliant.

Does Novartis Brasil have PCI DSS certification ?

According to Rankiteo, Novartis Brasil does not currently maintain PCI DSS compliance.

Does Novartis Brasil comply with HIPAA ?

According to Rankiteo, Novartis Brasil is not compliant with HIPAA regulations.

Does Novartis Brasil have ISO 27001 certification ?

According to Rankiteo,Novartis Brasil is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Novartis Brasil operate in ?

Novartis Brasil operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Novartis Brasil have ?

Novartis Brasil employs approximately 346 people worldwide.

Does Novartis Brasil own any subsidiaries ?

Novartis Brasil presently has no subsidiaries across any sectors.

How many LinkedIn followers does Novartis Brasil have ?

Novartis Brasil's official LinkedIn profile has approximately 149,378 followers.

What is the NAICS classification code for Novartis Brasil ?

Novartis Brasil is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Novartis Brasil have a Crunchbase profile ?

No, Novartis Brasil does not have a profile on Crunchbase.

Does Novartis Brasil have a LinkedIn profile ?

Yes, Novartis Brasil maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/novartisbrasil.

How many cybersecurity incidents has Novartis Brasil experienced ?

As of October 2, 2026, Rankiteo reports that Novartis Brasil has experienced 2 cybersecurity incidents.

How many peer or competitor companies does Novartis Brasil have ?

Novartis Brasil has an estimated 5,771 peer or competitor companies worldwide.

What types of cybersecurity incidents has Novartis Brasil faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach and Cyber Attack.

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Novartis Brasil

Boost Score +25 with badge (5 left)

758

/1000

Fair

783

/1000

Fair

Novartis Brasil Vendor Cyber Rating & Cyber Score

novartis.com.br

Add Your Compliance Badge

A Novartis está reimaginando a medicina para melhorar e estender a vida das pessoas. Como líder mundial em medicamentos, usamos ciência inovadora e tecnologias digitais para criar tratamentos transformadores em áreas médicas de grande impacto. Em nossa busca por novos medicamentos, estamos constantemente entre as principais empresas do mundo que mais investem em pesquisa e desenvolvimento. Os produtos Novartis atingem quase um bilhão de pessoas em todo o mundo e estamos descobrindo maneiras inovadoras de expandir o acesso aos nossos tratamentos mais recentes. Cerca de 125 000 pessoas de mais de 140 nacionalidades trabalham na Novartis em todo o mundo. Veja nossas regras de comunidade:

Novartis Brasil

Novartis Brasil CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Novartis

Breach

2/2026

NOV1774449180

Novartis Brasil

Cyber Attack

100

06/2022

NOV21267722

Loading…

A.I.

Novartis Brasil Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Novartis Brasil

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Brasil in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Novartis Brasil in 2026.

Incident Types Novartis Brasil vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Brasil in 2026.

Incident History - Novartis Brasil (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Novartis Brasil Subsidiaries

Novartis Brasil

Pharmaceutical Manufacturing

Website: https://www.novartis.com.br/

Company Size: 346

NovartisPharmaceutical Manufacturing

Novartis IndiaPharmaceutical Manufacturing

Novartis SciencePharmaceutical Manufacturing

Novartis Gene TherapiesBiotechnology Research

Novartis SlovakiaPharmaceutical Manufacturing

Novartis NorgePharmaceutical Manufacturing

Novartis BeluxPharmaceutical Manufacturing

Novartis DanmarkPharmaceutical Manufacturing

Novartis SverigePharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis FinlandPharmaceutical Manufacturing

Novartis, Australia & New ZealandPharmaceutical Manufacturing

Novartis MagyarországPharmaceutical Manufacturing

Novartis USPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis ItaliaPharmaceutical Manufacturing

Novartis SerbiaPharmaceutical Manufacturing

Novartis IsraelPharmaceutical Manufacturing

Novartis Hong KongPharmaceutical Manufacturing

Novartis MedicalPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis NederlandPharmaceutical Manufacturing

Novartis Nederland - NeurologieGeneesmiddelenproductie

Novartis Nederland - OncologieGeneesmiddelenproductie

Novartis Nederland - ReumatologieGeneesmiddelenproductie

Novartis Nederland - HematologieGeneesmiddelenproductie

Novartis Nederland - DermatologieGeneesmiddelenproductie

Novartis Nederland - Cardiovascular, Renal & Metabolism Geneesmiddelenproductie

Novartis MéxicoPharmaceutical Manufacturing

Novartis EspañaPharmaceutical Manufacturing

Novartis DeutschlandPharmaceutical Manufacturing

Novartis PortugalPharmaceutical Manufacturing

Novartis ColombiaPharmaceutical Manufacturing

Novartis Gulf | نوفارتس الخليجPharmaceutical Manufacturing

Novartis US MedicalPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis CanadaPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis in SloveniaPharmaceutical Manufacturing

Novartis Ireland Pharmaceutical Manufacturing

Novartis RomâniaPharmaceutical Manufacturing

Novartis ArgentinaPharmaceutical Manufacturing

Novartis SingaporePharmaceutical Manufacturing

Loading…

Novartis Brasil Similar Companies

SUN PHARMA

sunpharma.com

Sun Pharma is the world's fourth-largest speciality generic pharmaceutical company and No. 1 in India. We provide high-quality, affordable medicines trusted by customers and patients in over 100 countries. Sun Pharma's global presence is supported by more than 40 manufacturing facilities spread across 5 continents, R&D centres across the globe, and a multicultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising around 3,000 scientists and R&D investments of over 6-8% of annual revenues. At Sun, our people are our greatest asset. Ours has never been a story of individual brilliance but of cultivating a culture of realising collective potential. In our journey, everyone is enabled to take charge in an environment that offers limitless growth opportunities. We are with you every step of the way, so you can shine for years to come. With the launch of our Employee Value Proposition (EVP), we define our promise to ‘Create Your Own Sunshine'—driven by the three pillars of Better Every Day, Take Charge, and Thrive Together. These pillars drive progress at Sun so that people can achieve what they would have thought impossible. Learn more about our EVP here: https://sunpharma.com/careers/

Lonza

lonza.com

Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.

Sandoz

sandoz.com

Sandoz is the global leader in generic and biosimilar medicines. Our Purpose is to pioneer access to medicines for patients globally. We are on a mission to drive innovation in the healthcare industry by freeing up resources sustainably and responsibly while continuing to address global health challenges such as antimicrobial resistance. We are present in more than 100 countries and our medicines serve some 500 million people every year. We have two main global businesses: Generics - divided between standard generics and complex generics - and Biosimilars. Read our community engagement guidelines: http://bit.ly/4ofoggc

Novo Nordisk

cb novonordisk.com

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 68,800 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

Teva Pharmaceuticals

tevapharm.com

Teva Pharmaceuticals is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how we make it happen, visit www.tevapharm.com. Our community guidelines may be found here: https://www.tevapharm.com/news-and-media/teva-social-media-guidelines/ Please note that adverse effects for any of our products should be reported at: https://www.tevapharm.com/teva-medical-information/report-a-side-effect-form/ Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details and Teva's Pharmacovigilance Privacy Policy may be found here: http://www.tevapharm.com/contact_us/

AbbVie

cb abbvie.com

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

Grifols

cb linktr.ee

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth. People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers. In 2024, Grifols was named one of TIME’s ‘World’s Best Companies’ for the second year in a row, reaffirming our commitment to excellence. We were also recognized by Forbes as one of the "Best Employers for Women 2023," reflecting our dedication to fostering an inclusive and supportive workplace for all. To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.

Servier

servier.com

Servier is an independent international pharmaceutical group governed by a foundation. With its unique governance model, the Group is committed to therapeutic progress to serve patients and integrates the patient voice at every stage of the medicine life cycle. As a leading global player in cardiology and venous diseases, Servier aims to become a leading innovator in oncology and neurology. Through precision medicine, the Group intends to offer targeted therapeutic solutions for a limited number of rare diseases and invests nearly 20% of its brand-name sales in R&D. Headquartered in France, Servier relies on its more than 20,000 employees and a solid geographic presence with medicines distributed in more than 130 countries. In the 2024/25 financial year, the Group achieved revenues of €6.9 billion. -- To report a suspected adverse event with a Servier drug, please visit servier.com

AUROBINDO PHARMA LTD

aurobindo.com

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, branded specialty drugs, and active pharmaceutical ingredients (APIs) across more than 150 countries. It is ranked among the top 10 generic companies in eight European nations and holds the distinction of being the largest generic pharmaceutical company in the United States. With over 30 state-of-the-art manufacturing and packaging facilities approved by leading global regulatory authorities including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA, Aurobindo Pharma ensures the highest standards of quality. Its robust portfolio spans eight major therapeutic areas: Central Nervous System (CNS), Antiretroviral (ARV), Cardiovascular (CVS), Antibiotics, Gastroenterology, Anti-diabetics, Oncology, and Dermatology, supported by a strong R&D infrastructure that drives innovation, affordability, and accessibility.

Loading…

NEWS

Novartis Brasil CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

April 16, 2024 07:00 AM

Novartis appoints Beatriz Silveira as Global Security Regional Head for APAC

Beatriz Silveira: Prior to this, Beatriz was the director and head of technology for APAC, EMEA, and Europe regions at Citi,...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-103761

SUMMARY

Mooncake transfer engine through 0.3.13.post1 contains a memory exhaustion vulnerability in TransferMetadata::receivePeerNotify that allows unauthenticated attackers to grow process memory without limit. Attackers can repeatedly send notify frames up to 1 MB to the handshake RPC port, filling the uncapped notifys vector until the out-of-memory killer terminates the engine.

Published

Date2026-10-01

Updated

Date2026-10-01

RISK INFORMATION (Score: 7.5)

cvss3

Base Score: 7.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H

cvss4

Base Score: 8.7

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.6

Exploitability

3.9

REFERENCES

CVE-2026-103760

SUMMARY

Mooncake transfer engine through 0.3.13.post1 contains a denial of service vulnerability that allows unauthenticated remote attackers to block the handshake daemon by never reading replies. Attackers can send a Metadata request to the handshake RPC port and stall SocketHandShakePlugin's single listener thread in writeFully(), breaking all subsequent handshakes, metadata fetches, notify and probe requests.

Published

Date2026-10-01

Updated

Date2026-10-01

RISK INFORMATION (Score: 5.9)

cvss3

Base Score: 5.9

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:N/I:N/A:H

cvss4

Base Score: 8.2

Complexity: HIGH

CVSS:4.0/AV:N/AC:H/AT:P/PR:N/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.6

Exploitability

2.2

REFERENCES

CVE-2025-71427

SUMMARY

Office-PowerPoint-MCP-Server through 2.0.7 contains a path traversal vulnerability that allows MCP callers to write and read files outside the working directory by supplying absolute paths or ../ sequences. Attackers can steer an AI agent via prompt injection to abuse save_presentation, open_presentation, or manage_image output_path to overwrite any server-writable file or load external files.

Published

Date2026-10-01

Updated

Date2026-10-01

RISK INFORMATION (Score: 6.8)

cvss3

Base Score: 6.8

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:R/S:U/C:H/I:H/A:N

cvss4

Base Score: 7.6

Complexity: HIGH

CVSS:4.0/AV:N/AC:H/AT:P/PR:N/UI:P/VC:H/VI:H/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.2

Exploitability

1.6

REFERENCES

CVE-2026-86344

SUMMARY

A flaw was found in 389-ds-base. An unauthenticated remote attacker can send a complete LDAP operation followed by the first bytes of an incomplete LDAPMessage on the same connection, causing the server to hand that connection to a second worker thread before the first worker's result is flushed. The second worker blocks until nsslapd-ioblocktimeout while holding the connection mutex, preventing delivery of the completed operation's result. Repeating this across a small number of connections proportional to the configured worker-thread pool size exhausts the entire pool under default configuration, denying service to all clients (anonymous and authenticated, plaintext and TLS) for as long as the attacker maintains the connections.

Published

Date2026-10-01

Updated

Date2026-10-01

RISK INFORMATION (Score: 7.5)

cvss3

Base Score: 7.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

3.9

REFERENCES

CVE-2026-71454

SUMMARY

Improper neutralization of input during web page generation ('cross-site scripting') vulnerability in CWE-79 - Cross-site Scripting CAPEC-63 allows Cross-Site Scripting (XSS). This issue affects CAPEC-63: before 3.0b63.

Published

Date2026-10-01

Updated

Date2026-10-01

RISK INFORMATION (Score: )

cvss4

Base Score: 5.8

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:H/SI:H/SA:H/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

https://www.johnsoncontrols.com/trust-center/cybersecurity/security-advisories

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…

Badge your company to reduce your risk score and your cyber insurance costs!

Trusted by insurers. Chosen by leaders.

Novartis Brasil Vendor Cyber Rating & Cyber Score

Novartis Brasil A.I CyberSecurity Scoring

Novartis Brasil CyberSecurity News & History

Novartis Brasil Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Novartis Brasil

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Novartis Brasil vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - Novartis Brasil (X = Date, Y = Severity)

Novartis Brasil Subsidiaries

Novartis Brasil

Novartis Brasil Similar Companies

SUN PHARMA

Lonza

Sandoz

Novo Nordisk

Teva Pharmaceuticals

AbbVie

Grifols

Servier

AUROBINDO PHARMA LTD

Novartis Brasil CyberSecurity News

Novartis appoints Beatriz Silveira as Global Security Regional Head for APAC

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo

Novartis Brasil CyberSecurity News & History

Novartis Brasil Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Novartis Brasil

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Novartis Brasil vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - Novartis Brasil (X = Date, Y = Severity)

Novartis Brasil Subsidiaries

Novartis Brasil

Novartis Brasil Similar Companies

SUN PHARMA

Lonza

Sandoz

Novo Nordisk

Teva Pharmaceuticals

AbbVie

Grifols

Servier

AUROBINDO PHARMA LTD

Novartis Brasil CyberSecurity News

Novartis appoints Beatriz Silveira as Global Security Regional Head for APAC

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo